Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques

/in

Aid M, Colarusso A, Walker-Sperling V, Barouch DH. Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques. Cell Rep Med. 2023 Jul 18;4(7):101122. doi: 10.1016/j.xcrm.2023.101122. PMID: 37467721; PMCID: PMC10394255.

Resilience as a potential modifier of racial inequities in preterm birth

/in

Redhunt AM, Ledyard R, Collier AY, Hacker MR, Burris HH. Resilience as a potential modifier of racial inequities in preterm birth. Ann Epidemiol. 2023 Jul;83:54-59.e1. doi: 10.1016/j.annepidem.2023.04.010. Epub 2023 Apr 22. PMID: 37088321; PMCID: PMC10330189.

Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage

/in

Wagh K, Seaman MS. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage. Curr Opin HIV AIDS. 2023 Jul 1;18(4):164-170. doi: 10.1097/COH.0000000000000800. Epub 2023 May 19. PMID: 37249911; PMCID: PMC10256304.

Attenuated Mycobacterium tuberculosis vaccine protection in a low-dose murine challenge model

/in ,

Vidal SJ, Sellers D, Yu J, Wakabayashi S, Sixsmith J, Aid M, Barrett J, Stevens SF, Liu X, Li W, Plumlee CR, Urdahl KB, Martinot AJ, Barouch DH. Attenuated Mycobacterium tuberculosis vaccine protection in a low-dose murine challenge model. iScience. 2023 May 28;26(6):106963. doi: 10.1016/j.isci.2023.106963. PMID: 37378347; PMCID: PMC10291467.

Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions

/in ,

Bartsch YC, Cizmeci D, Kang J, Gao H, Shi W, Chandrashekar A, Collier AY, Chen B, Barouch DH, Alter G. Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions. iScience. 2023 May 19;26(5):106582. doi: 10.1016/j.isci.2023.106582. Epub 2023 Apr 7. PMID: 37082529; PMCID: PMC10079316.

Isolation of a rhesus calicivirus that can replicate in human cells

/in

Gan T, Droit L, Vernon S, Barouch DH, Wang D. Isolation of a rhesus calicivirus that can replicate in human cells. Virology. 2023 May;582:83-89. doi: 10.1016/j.virol.2023.03.012. Epub 2023 Apr 2. PMID: 37031656; PMCID: PMC10264158.

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

/in

Yu J, Thomas PV, Sciacca M, Wu C, Liu J, He X, Miller J, Hachmann NP, Surve N, McMahan K, Jacob-Dolan C, Powers O, Hall K, Barrett J, Hope D, Mazurek CR, Murdza T, Chang WC, Golub E, Rees PA, Peterson CE, Hajduczki A, Chen WH, Martinez EJ, Hussin E, Lange C, Gong H, Matyas GR, Rao M, Suthar M, Boursiquot M, Cook A, Pessaint L, Lewis MG, Andersen H, Bolton DL, Michael NL, Joyce MG, Modjarrad K, Barouch DH. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. Cell Rep Med. 2023 Apr 18;4(4):101018. doi: 10.1016/j.xcrm.2023.101018. Epub 2023 Mar 27. PMID: 37023746; PMCID: PMC10040355.

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

/in , ,

Daniel J Stieh, Dan H Barouch, Christy Comeaux, Michal Sarnecki, Kathryn E Stephenson, Stephen R Walsh, Sheetal Sawant, Jack Heptinstall, Georgia D Tomaras, James G Kublin, M Juliana McElrath, Kristen W Cohen, Stephen C De Rosa, Galit Alter, Guido Ferrari, David Montefiori, Philipp Mann, Steven Nijs, Katleen Callewaert, Paul A Goepfert, Srilatha Edupuganti, Etienne Karita, Michael S Seaman, Lawrence Corey, Lindsey R Baden, Maria G Pau, Hanneke Schuitemaker, Frank Tomaka, the ASCENT/HVTN118/HPX2003 Study Team , Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study, The Journal of Infectious Diseases, Volume 227, Issue 8, 15 April 2023, Pages 939–950, https://doi.org/10.1093/infdis/jiac445

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

/in

Solforosi, L., Costes, L.M.M., Tolboom, J.T.B.M. et al. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. Nat Commun 14, 1944 (2023). https://doi.org/10.1038/s41467-023-37715-2

Progress in vaccine development for infectious diseases—a Keystone Symposia report

/in

Cable J, Graham BS, Koup RA, Seder RA, Karikó K, Pardi N, Barouch DH, Sharma B, Rauch S, Nachbagauer R, Forsell MNE, Schotsaert M, Ellebedy AH, Loré K, Irvine DJ, Pilkington E, Tahtinen S, Thompson EA, Feraoun Y, King NP, Saunders K, Alter G, Moin SM, Sliepen K, Karlsson Hedestam GB, Wardemann H, Pulendran B, Doria-Rose NA, He WT, Juno JA, Ataca S, Wheatley AK, McLellan JS, Walker LM, Lederhofer J, Lindesmith LC, Wille H, Hotez PJ, Bekker LG. Progress in vaccine development for infectious diseases-a Keystone Symposia report. Ann N Y Acad Sci. 2023 Jun;1524(1):65-86. doi: 10.1111/nyas.14975. Epub 2023 Apr 5. PMID: 37020354.